Cell therapy expert Lindsay Davies, PhD, FHEA, discusses the key considerations for moving the needle to broader adoption of CGTs in Europe.
The development of cell and gene therapies (CGTs) is a dynamic and evolving area, challenging technology, legislation and financial models for the pharmaceutical industry. CGTs have positioned themselves as the new superhero drugs, swooping in to challenge unmet clinical needs, with the potential to establish new cures for previously life-limiting conditions and opportunities for one-time approaches to treating diseases.
Europe’s position in the advanced therapy market
As a hub for innovation and scientific excellence, Europe is serving as a gateway for many new drug candidates and novel drug targets. However, investment to bring these novel treatments to market in the region is a challenge. Many drugs in early development are being siphoned by large Pharma or major investors and transitioned into the North American system to complete their development and market approval.
The recent shift in global geopolitics has rippled through the financial markets, changes that have strongly impacted the pharmaceutical industry. For Europe, this has been an opportunity to demonstrate the advantages of developing such high value drugs within the region.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
As a firm competitor to the US market for the entire product lifecycle, Europe has marketed itself as a diverse, strong market that enables pharmaceutical businesses to establish themselves, invest and grow within the region.
[For Europe,] the recent shift in global geopolitics… has been an opportunity to demonstrate the advantages of developing such high value drugs within the region”
Individual EU governments are establishing initiatives to support companies and academics with new concepts to spin out into the commercial sector, heavily investing especially within the CGT sector. This includes initiatives such as ATMP 2030 led out of Sweden. Regional hubs, specialising in CGT manufacturing, process and product development and training to increase specialised workforces within the region have also been established, and thrive.
This shift in business model, to keep investigational drugs inside of Europe is impacting the ancillary service industry as well, with strong investment in contract manufacturing spaces, new quality control analytics companies and hubs for raw materials such as cell culture media.
Of course, the ultimate aim is not to shift the primary region for developing CGTs, but rather see a wealth of knowledge, experience and opportunities across the globe. Collaboration and alliance are key to the successful integration of CGTs globally into standard healthcare.
Addressing the challenges of cell and gene therapy development and market entry
Society faces unique, global challenges with the evolution and establishment of CGTs in medical practice. These include:
Manufacturing, CMC and scalability
Collaboration and alliance are key to the successful integration of [cell and gene therapies] globally into standard healthcare”
The lack of technological solutions to manufacturing and scaling of production was once the core issue facing CGT developers.
However, scalability now enters the debate of centralised versus decentralised manufacturing. This risk-based approach, considering the product on a case-by-case basis and bespoke to product development strategy truly highlights the unique challenges the industry faces.
The speed of advancements in engineering, digitalisation, artificial intelligence (AI) and product design far outpaces the speed at which regulations move, however. The introduction of rapid microbial methods being one such example, with global regulators having different viewpoints on the introduction of these technologies, moving away from traditional compendial methods.
While regulators are in favour of advancements that benefit the patient through accessibility and speed of manufacturing and drug product release, caution remains, safeguarding the patient until technology has proven itself through risk management, comparability testing against compendial methods and, within Europe, stringent validation and QP approval.
Regulatory alignment and harmonisation
A need for regulatory alignment and harmonisation across jurisdictions, to truly move towards global availability of such specialist drug products, has received much attention recently.
For example, the US Food and Drug Administration (FDA), Japanese PMDA and the European Medicines Agency (EMA) are aligning their requirements while minimising risk to patient safety or product quality. Many CGTs have also taken advantage of expedited market entry schemes and exclusivity options.
Investment and reimbursement
Innovative medicines such as CGTs are associated with high costs. The traditional route to market through clinical trials offers unique challenges to CGT developers from onboarding investors, through to payment for the resulting drug itself.
Reimbursement remains one of the true open questions right now. Of course, the aim is to have equal access across all EU Member States, eliminating the risk that CGTs become a premium product. At present, the EU has a single regional approach to pricing. While there may be economy in scale, the challenge is to model how new drugs on the market will be valued. There needs to be balance, especially for a global marketing strategy where drug prices are historically higher in regions such as the US to that of Europe.
Where Europe exhibits strength in innovation, many countries demonstrate a creative and solution-driven environment. A collaborative approach will help deliver successful adoption of new therapeutic modalities, especially considering the current challenges of CGT development.
About the author
Lindsay Davies is Vice President Elect for Europe at the International Society for Cell & Gene Therapy (ISCT), sitting on the European Task Force and several committees related to process development and commercialisation, as well as the inaugural Chair for ISCT’s European Industry committee. She is also an industry representative for the Swedish national ATMP coordinating team and member of multiple Boards for European societies and corporate entities.
Dr Davies set up her own consulting company in 2020, before joining cell therapy company NextCell Pharma as Chief Scientific Officer. In 2024, Dr Davies co-founded QVance, a subsidiary of NextCell Pharma, specialising in quality control analytics service provision for advanced therapy developers.
Prior to this, she worked as an Associate Professor at the Karolinska Institutet, Sweden, and the Finnish Red Cross Blood Service and an industrial partner in developing a new medical device for burns therapy.
She completed her PhD in biochemistry in 2006 at Cardiff University, UK, focusing on cell therapy, before starting with a postdoc and two fellowship positions in stem/stromal cell biology. During this time, Dr Davies discovered a novel stem cell population within the oral cavity, which she patented and won multiple awards related to this work.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.